This site is intended for healthcare professionals only

In association with the Cardiorenal Forum

Articles

  • Use and safety of finerenone in a routine setting: first interim results from FINE-REAL

  • Obese man in clinic

    A promising FLOW of repurposed pharmacological therapies in people with CKD in type 2 diabetes

  • Human kidneys concept

    Semaglutide improves chronic kidney disease in people with type 2 diabetes

  • Man taking pill

    SGLT2i kidney outcome trial participants vs a real-world population

  • SGLT2 inhibitors versus GLP-1 receptor agonists for renal patients: does it matter?

  • Pharmacist considering medications

    Novel antidiabetes drugs improve composite renal outcomes

  • RAAS inhibition combinations and risk of acute kidney injury and hyperkalaemia in diabetic kidney disease

  • Glucose-lowering medications and comparative kidney outcomes in type 2 diabetes

  • The safety of sodium–glucose cotransporter-2 inhibitors in people with chronic kidney disease and type 2 diabetes

    The safety of sodium–glucose cotransporter-2 inhibitors in people with chronic kidney disease and type 2 diabetes

alt

For the latest news and articles
Sign up to Renal Review newsletters

Subscribe